Lab Companies See Massive Layoffs and Restructuring
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LAB INDUSTRY REPORT
NATIONAL LAB REPORTER
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.
A high volume of FDA approvals for new tests and diagnostic products made up for the relatively low number of approvals in the EU.
Automating travel and expense significantly improves performance, but adding mobility takes such improvements to a much higher level.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
Solutions you can implement right away to address current lab staffing concerns and prepare for the future.
Increasing incidences of heart disease, as well as technological advances, will drive growth over the next eight to 10 years, reports say.
According to a recent report, digital health companies are on track to rake in $21 billion for 2022, below the 2021 total of $29.1 billion.
Continuing recent patterns, M&A deal-making in the diagnostics space was low in volume but high in impact in October.
While new test approvals were scarce in October, they were particularly impactful; here are three approvals you should know about.